ribCVS Caremark®

|  |
| --- |
| Reference number(s) |
| 2104-A |

# Specialty Guideline Management Kisqali Femara Co-Pack

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
| --- | --- |
| Kisqali Femara Co-Pack | ribociclib tablets; letrozole tablets |

## Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### FDA-approved Indications1

Kisqali Femara Co-Pack is indicated for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence.

Kisqali Femara Co-Pack is indicated as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.

### Compendial Uses2

* Breast cancer
* Endometrial carcinoma

All other indications are considered experimental/investigational and not medically necessary.

## Documentation

Submission of the following information is necessary to initiate the prior authorization review:

* For members requesting initiation of therapy for the treatment of breast cancer: documentation of hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status.
* For members requesting initiation of therapy for the treatment of endometrial carcinoma: documentation of laboratory results confirming estrogen receptor (ER) status.

## Coverage Criteria

### Breast cancer1,2

Authorization of 12 months may be granted to members for the treatment of HR-positive, HER2-negative recurrent or metastatic breast cancer.

Authorization of 12 months may be granted to members for adjuvant treatment of HR-positive, HER2-negative early-stage breast cancer at high risk of recurrence (e.g., any lymph node involvement (excluding microscopic nodal involvement), or no nodal involvement and tumor size greater than 5 cm, or tumor size is 2 to 5 cm and Grade 2 (and high genomic risk or Ki-67 greater than or equal to 20%) or Grade 3).

### Endometrial carcinoma2

Authorization of 12 months may be granted to members for treatment of recurrent or metastatic endometrial carcinoma with ER-positive tumors.

## Continuation of Therapy

### Early Breast Cancer

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for adjuvant treatment of early-stage, HR-positive, HER2-negative breast cancer with high risk of recurrence until completion of 3 years of treatment or until disease recurrence or unacceptable toxicity while on the current regimen.

### Recurrent or Metastatic Breast Cancer or Endometrial Carcinoma

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for recurrent or metastatic breast cancer or endometrial carcinoma when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

## References

1. Kisqali Femara Co-Pack [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2024.
2. Ribociclib. The NCCN Drugs & Biologics Compendium® © 2025 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed July 21, 2025.